From cloudy to clear: visualising complex data privacy information
April 17, 2026 | clinical trials, communication, health literacy
Discover how clear communication principles can transform complex clinical research topics, as we conclude our Health Literacy series with a practical example on participant data transparency.
For the final instalment of our Health Literacy series, we’re sharing another example of how we apply clear communication principles in practice. Here, we explore how we approached a crucial topic in clinical research: participant data.
Medical data is private – it’s sensitive and not something you want to share with strangers. The lack of transparency around how clinical trial data is stored and used can be a major barrier to participation, particularly for underrepresented communities.
We understand the complexity that comes with this topic. There are so many regulations, nuances, and technicalities to consider, which often means the information reads like a Terms & Conditions page. Although the reader has been “informed”, have they really read it? And more importantly, do they really understand?
Our “before” and “after” example shows how a simple flow diagram can help to translate this critical information so anyone can understand how their personal data may be shared.
Before:
The language is contractual and uses technical terms withoutcontext. It’s difficult to know what data your doctor, a researcher, or thebroader scientific community might be able to see.
After:
We’ve broken this information down into a flow diagram, clearly calling out the steps in place to ensure personal data are not identifiable. We made use of visual cues to emphasise that the data becomes more difficult to identify when it is processed and shared. Finally, using real examples of the types of data that may be collected helps provide the transparency readers are looking for.
Ultimately, we’ve provided a clear, visual commitment, supported with examples, to illustrate exactly how readers can expect their personal data to be used.
Clear communication about participant data isn’t just a regulatory requirement – it’s essential for building trust in clinical research. By presenting complex information in ways that people can easily understand, we can help more participants make informed decisions about taking part in clinical trials.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Why fresh patient voices are critical to improve clinical trials outcomes
Discover why diverse patient voices, especially first-time participants, are key to improving clinical trials. Boost recruitment, retention, and patient-centric research.
Using patient personas to add a personal touch to clinical trial recruitment and retention
Discover how patient personas can revolutionise clinical trial recruitment and retention. Personalise outreach, build trust, and improve patient engagement.
A month of insights: Key takeaways from May’s conferences
Explore key insights from some of May’s top healthcare conferences, covering patient engagement, health equity, co-creation, and tech innovation shaping clinical trials.
Cuttsy+Cuttsy and ISPEP highlight key patient insights in new clinical trials report
Explore how Cuttsy+Cuttsy and ISPEP are spotlighting patient engagement in clinical trials through a new global report.
Motivations that matter: Understanding clinical trial participation to create better research
Understanding why people join clinical trials is essential to improving recruitment and designing better research. Explores the diverse motivations driving participation — from altruism and hope for better health to...
Cuttsy+Cuttsy welcomes new team members and celebrates a familiar face returning
Cuttsy+Cuttsy proudly announces the expansion of its team with the addition of three new hires—Michelle, Jay, and Emily—and the welcome return of former team member Sally as Account Director.
AI and away we go: key insights from Reuters Pharma 2025
AI is revolutionising the pharmaceutical industry, as highlighted at Reuters Pharma 2025, with transformative applications across marketing, drug discovery, and patient engagement, despite challenges in adoption, regulation, and data trust.
Exciting updates from our content and strategy team
Cuttsy+Cuttsy celebrates new beginnings with the appointment of Oli Bailey as Strategy Director and recognises team excellence through several well-deserved promotions.
How is generative AI transforming clinical trials?
Discover how generative AI is revolutionising clinical trials, from enhancing patient recruitment to improving data analysis.
Content for all – how to connect with neurodiverse audiences
Discover essential strategies for crafting inclusive and accessible written content tailored for neurodivergent readers.